1,760
Views
27
CrossRef citations to date
0
Altmetric
Original Research

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

, , , , , , , & show all
Article: e1202391 | Received 20 Apr 2016, Accepted 12 Jun 2016, Published online: 11 Aug 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Edda Blümel, Shamaila Munir Ahmad, Claudia Nastasi, Andreas Willerslev-Olsen, Maria Gluud, Simon Fredholm, Tengpeng Hu, Bas G. J. Surewaard, Lise M. Lindahl, Hanne Fogh, Sergei B. Koralov, Lise Mette Rahbek Gjerdrum, Rachael A. Clark, Lars Iversen, Thorbjørn Krejsgaard, Charlotte Menné Bonefeld, Carsten Geisler, Jürgen C. Becker, Anders Woetmann, Mads Hald Andersen, Terkild Brink Buus & Niels Ødum. (2020) Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma. OncoImmunology 9:1.
Read now
Morten Orebo Holmström, Caroline Hasselbalch Riley, Vibe Skov, Inge Marie Svane, Hans Carl Hasselbalch & Mads Hald Andersen. (2018) Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. OncoImmunology 7:6.
Read now

Articles from other publishers (25)

Rasmus Erik Johansson Mortensen, Morten Orebo Holmström, Thomas Landkildehus Lisle, Jane P Hasselby, Gro L Willemoe, Özcan Met, Inge Marie Svane, Julia Johansen, Dorte L Nielsen, Inna M Chen & Mads Hald Andersen. (2023) Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. Journal for ImmunoTherapy of Cancer 11:3, pages e006432.
Crossref
Yunchao Zhang, Chenxin Liu, Chunjie Wu & Linjiang Song. (2023) Natural peptides for immunological regulation in cancer therapy: Mechanism, facts and perspectives. Biomedicine & Pharmacotherapy 159, pages 114257.
Crossref
Mads Hald Andersen. (2022) Tumor microenvironment antigens. Seminars in Immunopathology 45:2, pages 253-264.
Crossref
Jacob Handlos Grauslund, Morten Orebo Holmström, Evelina Martinenaite, Thomas Landkildehus Lisle, Hannah Jorinde Glöckner, Daniel El Fassi, Uffe Klausen, Rasmus E. J. Mortensen, Nicolai Jørgensen, Lasse Kjær, Vibe Skov, Inge Marie Svane, Hans Carl Hasselbalch & Mads Hald Andersen. (2023) An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. Frontiers in Immunology 14.
Crossref
Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, Morten Orebo Holmström, Helle Westergren Hendel, Eva Ehrnrooth, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen & Inge Marie Svane. (2021) A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nature Medicine 27:12, pages 2212-2223.
Crossref
Ritika Luthra, Shreeja Datta & Arpita Roy. (2021) Role of Different Peptides for Cancer Immunotherapy. International Journal of Peptide Research and Therapeutics 27:4, pages 2777-2793.
Crossref
Rupal Ojha & Vijay Kumar Prajapati. (2021) Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity. Journal of Cellular Physiology 236:12, pages 8020-8034.
Crossref
J. Tobias, P. Steinberger, M. Drinić & U. Wiedermann. (2021) Emerging targets for anticancer vaccination: PD-1. ESMO Open 6:5, pages 100278.
Crossref
Ming Wu, Sheng Wang, Jian-Yu Chen, Li-Juan Zhou, Zi-Wen Guo & Yu-Hua Li. (2021) Therapeutic cancer vaccine therapy for acute myeloid leukemia. Immunotherapy 13:10, pages 863-877.
Crossref
Morten Orebo Holmström, Rasmus Erik Johansson Mortensen, Angelos Michail Pavlidis, Evelina Martinenaite, Stine Emilie Weis-Banke, Mia Aaboe-Jørgensen, Simone Kloch Bendtsen, Özcan Met, Ayako Wakatsuki Pedersen, Marco Donia, Inge Marie Svane & Mads Hald Andersen. (2021) Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner. Cellular & Molecular Immunology 18:2, pages 415-426.
Crossref
Pottayil G. Sasikumar & Murali Ramachandra. (2020) Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy. Medicine in Drug Discovery 8, pages 100073.
Crossref
Nicolai Grønne Jørgensen, Uffe Klausen, Jacob Handlos Grauslund, Carsten Helleberg, Thomas Granum Aagaard, Trung Hieu Do, Shamaila Munir Ahmad, Lars Rønn Olsen, Tobias Wirenfeldt Klausen, Marie Fredslund Breinholt, Morten Hansen, Evelina Martinenaite, Özcan Met, Inge Marie Svane, Lene Meldgaard Knudsen & Mads Hald Andersen. (2020) Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial. Frontiers in Immunology 11.
Crossref
Mie Linder Hübbe, Ditte Elisabeth Jæhger, Thomas Lars Andresen & Mads Hald Andersen. (2020) Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade. Frontiers in Immunology 11.
Crossref
Morten Orebo Holmström, Hans Carl Hasselbalch & Mads Hald Andersen. (2020) Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers 12:7, pages 1763.
Crossref
Gholamreza Rezaei Danbaran, Saeed Aslani, Nadia Sharafkandi, Maryam Hemmatzadeh, Ramin Hosseinzadeh, Gholamreza Azizi, Farhad Jadidi-Niaragh, Farhad Babaie & Hamed Mohammadi. (2020) How microRNAs affect the PD-L1 and its synthetic pathway in cancer. International Immunopharmacology 84, pages 106594.
Crossref
Mingming Li, Xinran Zhao, Jianfang Dai & Zhilin Yu. (2019) Peptide therapeutics and assemblies for cancer immunotherapy多肽药物及组装体在癌症免疫治疗中的应用. Science China Materials 62:11, pages 1759-1781.
Crossref
Weizhi Wang & Zhiyuan Hu. (2018) Targeting Peptide‐Based Probes for Molecular Imaging and Diagnosis. Advanced Materials 31:45, pages 1804827.
Crossref
Mads Hald Andersen. (2018) The T-win® technology: immune-modulating vaccines. Seminars in Immunopathology 41:1, pages 87-95.
Crossref
Morten Orebo Holmström & Hans Carl Hasselbalch. (2018) Cancer immune therapy for myeloid malignancies: present and future. Seminars in Immunopathology 41:1, pages 97-109.
Crossref
Uffe Klausen, Staffan Holmberg, Morten Orebo Holmström, Nicolai Grønne Dahlager Jørgensen, Jacob Handlos Grauslund, Inge Marie Svane & Mads Hald Andersen. (2018) Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. Frontiers in Immunology 9.
Crossref
Mads Hald Andersen. (2018) The Balance Players of the Adaptive Immune System. Cancer Research 78:6, pages 1379-1382.
Crossref
Nyanbol Kuol, Lily Stojanovska, Kulmira Nurgali & Vasso Apostolopoulos. (2018) PD-1/PD-L1 in disease. Immunotherapy 10:2, pages 149-160.
Crossref
Zijun Y. Xu-MonetteJianfeng Zhou & Ken H. Young. (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:1, pages 68-83.
Crossref
Zijun Y. Xu-Monette, Mingzhi Zhang, Jianyong Li & Ken H. Young. (2017) PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology 8.
Crossref
Katerina Vavrova, Petra Vrabcova, Dominik Filipp, Jirina Bartunkova & Rudolf Horvath. (2016) Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy. Medical Oncology 33:12.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.